Hepatic Stem Cells Guide

Overview

Hepatic progenitor cells differentiated from UCT-WJ-MSCs; expressing liver-specific markers and capable of giving rise to hepatocytes and cholangiocytes for liver regeneration

Related: Stem Cells Overview • Hepatic Exosomes

FOR RESEARCH USE AND INTERNATIONAL USE ONLY

Specs	Details
Source	Derived from P2 UCT-WJ-MSCs via hepatic differentiation
Differentiation Protocol	Activin-A (definitive endoderm) → FGF-4 BMP-2 (hepatic specification) → HGF dexamethasone oncostatin M (hepatocyte maturation)
Cryopreservation	DMSO-free, glucose-based
Post-Thaw Viability	>98%
Storage	−80 °C long-term; −196 °C LN2 vapor phase for extended storage
Identity Markers	AFP⁺ (α-fetoprotein, early; absent at maturity), ALB⁺ (albumin), HNF4α⁺, CK18⁺, CK19⁺ (cholangiocyte-competent), EpCAM⁺, CD133⁺
Release Criteria	Albumin ELISA and urea synthesis assay confirm hepatocyte functional competence
Immunogenicity	HLA-DR⁻ (retained from UCT-WJ-MSC origin); immune-privileged for allogeneic delivery with reduced immunosuppression requirement vs cadaveric hepatocytes; non-tumorigenic (no teratoma risk vs iPSC/ESC sources)
Passage Limit	≤P2 from UCT-WJ-MSC
Manufacturing	cGMP, animal-product-free

Clinical Overview

Liver disease encompasses cirrhosis, acute liver failure, NASH, autoimmune hepatitis, and metabolic liver disorders — affecting an estimated 1.5 billion people globally and causing over 2 million deaths annually.^[1] Liver transplantation remains the only curative option for advanced disease, but donor scarcity, immunosuppression requirements, and surgical risks severely limit access. Akira Hepatic Stem Cells provide an off-the-shelf, immune-privileged hepatocyte-progenitor replacement therapy. Derived from UCT-WJ-MSCs, they carry the critical advantage of being non-tumorigenic (unlike ESC or iPSC-derived hepatocytes, which risk teratoma formation). In preclinical models, these cells engraft in damaged liver tissue, restore albumin production, reduce bilirubin, improve PT/INR, and dramatically reduce fibrosis through HGF-driven anti-fibrotic signaling. Exosomal cargo (miR-122, HGF, FGF-7) from Akira Hepatic Cells provides a cell-free liver regeneration option via the corresponding exosome product.

Process

Mechanism of Action

Hepatocyte Differentiation & Engraftment: HNF4α+/ALB+ hepatocytes engraft in the pericentral and periportal zones of damaged liver parenchyma via E-cadherin and integrin-β1 adhesion, establish gap junctions with host hepatocytes (connexin-32), and restore metabolic liver functions: albumin synthesis (restoring oncotic pressure, drug-binding capacity, and synthetic function); urea-cycle nitrogen metabolism (detoxifying ammonia, critical for hepatic encephalopathy prevention); CYP3A4/CYP2C9 drug-metabolism activity (improving pharmacokinetic management in liver failure); and bile acid conjugation via CK19+ ductal-competent cells contributing to cholangiocyte regeneration.

Anti-Fibrotic Paracrine — the Primary Clinical Mechanism: HGF is the master anti-fibrotic factor, binding Met on hepatic stellate cells (HSCs), suppressing TGF-β1-driven HSC activation, inducing HSC apoptosis, and activating MMP-9 for established collagen matrix degradation — including HGF-mediated regulation of cytotoxic CD8+ T-cell apoptosis in both normal and cirrhotic liver environments.^[2] miR-122, the liver-specific miRNA, suppresses TGF-β1 pro-fibrotic signaling and promotes hepatocyte-specific gene expression, an effect documented in TGF-β pathway targeting studies relevant to liver disease.^[3] IL-10/IDO suppress macrophage (including Kupffer cell) inflammatory activation, reducing hepatic NF-κB-driven fibrosis initiation. Decorin, a TGF-β-sequestering proteoglycan, further reduces active TGF-β availability in the hepatic stellate cell microenvironment.

Immunomodulation of Autoimmune Hepatitis: retained MSC immunosuppressive capacity (IDO, PGE2, TGF-β, IL-10) is intended to suppress CD4+/CD8+ T-cell attack on hepatocytes in autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis — addressing the immunological root of these conditions while simultaneously restoring hepatocyte mass. This immunomodulatory capacity mirrors the PGE2-mediated anti-inflammatory effects^[4] and M1 macrophage polarization suppression^[5] documented for MSCs more broadly across other inflammatory tissue contexts.

Cholangiocyte Competency: CK19+/EpCAM+ biliary progenitor derivatives address cholestatic diseases including primary biliary cholangitis and primary sclerosing cholangitis by restoring biliary epithelium integrity.

Biomarkers

Key Biomarkers & Molecular Cargo

Marker / Molecule	Functional Role
HNF4α (Hepatocyte Nuclear Factor 4α)	Master hepatocyte transcription factor; drives albumin, CYP450, and metabolic enzyme expression; required for mature hepatocyte identity
Albumin (ALB)	Primary liver synthetic function marker; confirms functional hepatocyte differentiation
CK18 / CK19	CK18: hepatocyte intermediate filament; CK19: cholangiocyte marker — dual expression confirms bipotent hepatic progenitor with ductal differentiation capacity
AFP (absent at maturity)	Absent AFP confirms mature hepatocyte phenotype vs. fetal hepatoblast — critical quality marker
EpCAM / CD133	Hepatic progenitor surface markers; EpCAM confirms epithelial hepatic identity, CD133 confirms progenitor self-renewal capacity
HGF	Primary anti-fibrotic and hepatoprotective factor; HSC activation suppression via Met receptor
miR-122 / miR-21	Liver-specific miRNA (miR-122) suppressing CTGF and TGF-β1; miR-21 in exosomal cargo modulates HSC activation
IL-10 / IDO / PGE2	Retained MSC immunosuppression — Kupffer cell suppression and T-cell modulation in autoimmune liver disease

Applications

Potential Applications

Acute Liver Failure (ALF): bridging therapy to transplant or native liver recovery — albumin restoration, ammonia detoxification, encephalopathy prevention.
Cirrhosis (any etiology): hepatocyte mass replacement; anti-fibrotic (HGF-driven stellate cell suppression); bilirubin and PT/INR improvement reported in MSC cirrhosis trials.
NASH / NAFLD: anti-inflammatory (Kupffer cell suppression), anti-fibrotic, lipid metabolism normalization, insulin sensitization.
Autoimmune Hepatitis: immunomodulation (IDO/IL-10) plus hepatocyte restoration — a dual mechanism addressing pathology and defect.
Primary Biliary Cholangitis (PBC): CK19+ cholangiocyte progenitors plus immunomodulation of T-cell-mediated biliary epithelial destruction.
Wilson's Disease: ATP7B-expressing hepatocytes contribute copper export capacity; paracrine support of remaining hepatocytes.
Alpha-1 Antitrypsin Deficiency: functional AAT-secreting hepatocytes replace deficient hepatocytes. Some models have shown wild-type donor hepatocytes progressively replace mutant-AAT-expressing host hepatocytes and resolve associated liver fibrosis^[6]; reduction of hepatocyte ER stress specifically is inferred from this reduced mutant-protein burden rather than directly measured.
Post-Transplant Hepatitis: immunomodulation of rejection while restoring hepatocyte synthetic function.

These are experimental use cases, provided as a scientific reference for researchers. Except where noted, they did not use Akira Biotech materials, and results may not be reproducible with ours. Akira Biotech supplies laboratory reagents for research use only. Our products are NOT approved by FDA or any regulatory authority and are not for use in or on humans.

Evidence

Clinical & Preclinical Evidence

Study / Trial	N / Design	Endpoints	Key Finding
UC-MSC in Liver Cirrhosis^[7]	n=40–80 per trial; Phase I/II; IV or hepatic artery	Child-Pugh, MELD, albumin, PT/INR, bilirubin	Child-Pugh improvement in the majority; albumin increase 3–5 g/L; bilirubin reduction 25–40%; PT/INR improvement — consistent across multiple trials
MSC in NASH (Phase II, ongoing)^[8]	Phase II RCT; biopsy-confirmed NASH F2–F4	NAS score, fibrosis stage, ALT, AST, liver stiffness	NAS score reduction; fibrosis stage improvement; ALT normalization in a subset — Phase II establishing the pathway
Hepatocyte Progenitor Preclinical (CCl4/BDL models)	Rat/mouse CCl4-cirrhosis and BDL models	Fibrosis score, collagen content, albumin, bilirubin, survival	60% fibrosis score reduction; collagen area reduced 55%; albumin normalized; 80% survival improvement in an acute liver failure model
Autoimmune Hepatitis MSC (Phase I)	n=10–20; autoimmune hepatitis; steroid-dependent	ALT, IgG, autoantibodies, liver histology, remission rate	ALT normalization; IgG reduction; ANA/SMA titer reduction; histologic activity improvement — steroid-sparing effect in the majority

Non-tumorigenicity is a key safety advantage of the UCT-MSC origin versus iPSC- or ESC-derived hepatocytes, which carry teratoma risk from residual pluripotent cells.^[9] HGF-mediated suppression of hepatic stellate cell activation through the TLR4/NF-κB pathway is well established in direct MSC co-culture models.^[10] The hepatic exosome product derived from these cells carries the same miR-122 and HGF cargo in a cell-free format.

Hepatic Stem Cells